We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Amgen (AMGN) is a biotech company based in California. It specializes in developing treatments for cardiovascular conditions, ...

Regeneron Pharmaceuticals (REGN) appealed a decision of the United States District Court for the Northern District of West Virginia denying ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Amgen has shared additional Phase 3 data for its rare disease drug Uplizna in myasthenia gravis, bolstering the company’s ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with ...

Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Amgen's Uplizna met key endpoints in a Phase 3 gMG trial, showing sustained efficacy and improvement in muscle function with ...